Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 9/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20140730 | 0.81 | SIGMAR1 (0.43) | NQO2NAMPTSIGMAR1 | |
| SCHEMBL20139813 | 0.79 | NAMPT (0.42) | DRD2ACACBACACANAMPT | |
| SCHEMBL20140007 | 0.76 | SLC6A2 (0.37) | DRD2DPP4 | |
| SCHEMBL3635639 | 0.75 | HTR2C (0.47) | DRD2DPP4 | |
| SCHEMBL31122858 | 0.75 | HTR2C (0.51) | DRD2DPP4 | |
| SCHEMBL20157262 | 0.75 | MTOR (0.43) | DRD2 | |
| SCHEMBL20157160 | 0.75 | DRD2 (0.53) | NQO2DRD2ACACBACACANAMPT | |
| SCHEMBL22957300 | 0.73 | NAMPT (0.51) | NAMPTFAAH | |
| SCHEMBL6990507 | 0.72 | DRD2 (0.48) | DRD2ACACBACACANAMPTSIGMAR1 | |
| SCHEMBL28258209 | 0.71 | DRD2 (0.47) | NQO2DRD2IDO1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018089433-A1 | PHENYL mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |